• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Evolent Health Inc (Amendment)

    4/9/24 1:17:52 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary
    Get the next $EVH alert in real time by email
    SC 13G/A 1 Evolent_Health_Inc.htm FILING EVOLENT HEALTH, INC. Schedule 13G


     
    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 08)*
     
    Evolent Health, Inc. 

    (Name of Issuer)
     
    Class A Common Stock, par value $0.01 per share

    (Title of Class of Securities)
     
    30050B101

    (CUSIP Number)
     
    March 29, 2024

    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
         x  Rule 13d-1(b)
     
         o  Rule 13d-1(c)
     
         o  Rule 13d-1(d)
     
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     


     
     

     
     
    CUSIP No.  30050B101            
     
               
    1   NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
      JPMORGAN CHASE & CO.

    13-2624428
         
    2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)



      (a)   o
      (b)   o
         
    3   SEC USE ONLY
       
       
         
    4   CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Delaware
           
    NUMBER OF SHARES BENEFICIALLY  OWNED BY EACH REPORTING PERSON WITH:  5   SOLE VOTING POWER
       
      4,111,488
         
    6   SHARED VOTING POWER
       
      3,079
         
    7   SOLE DISPOSITIVE POWER
       
      4,664,522
         
    8   SHARED DISPOSITIVE POWER
       
      3,131
         
    9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
      4,679,353
         
    10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
      o
         
    11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
      4.0 %
         
    12   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      HC
     

    FOOTNOTES
       
     
     
     

     
     
    Item 1.


     
    (a)
    Name of Issuer
     
     
    Evolent Health, Inc.


     
    (b)
    Address of Issuer’s Principal Executive Offices
     
     
    1812 N. Moore Street, Suite 1705,
    Arlington, Virginia 22209


    Item 2.


     
    (a)
    Name of Person Filing
     
     
    JPMORGAN CHASE & CO.


     
    (b)
    Address of Principal Business Office or, if none, Residence
     
     
    383 Madison Avenue
    New York, NY 10179


     
    (c)
    Citizenship
     
     
    Delaware


     
    (d)
    Title of Class of Securities
     
     
    Class A Common Stock, par value $0.01 per share


     
    (e)
    CUSIP Number
     
     
    30050B101


     
    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:


     
    (a)
    o
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).


     
    (b)
    o
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).


     
    (c)
    o
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).


     
    (d)
    o
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).


     
    (e)
    o
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);


     
    (f)
    o
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);


     
    (g)
    x
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);


     
    (h)
    o
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);


     
    (i)
    o
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);


     
    (j)
    o
    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).


     
    (k)
    o
    A group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:


     
     
     

     
     
    Item 4.
    Ownership.
     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.


     
    (a)
    Amount beneficially owned: 4,679,353


     
    (b)
    Percent of class: 4.0 %


     
    (c)
    Number of shares as to which the person has:


     
    (i)
    Sole power to vote or to direct the vote: 4,111,488


     
    (ii)
    Shared power to vote or to direct the vote: 3,079


     
    (iii)
    Sole power to dispose or to direct the disposition of: 4,664,522


     
    (iv)
    Shared power to dispose or to direct the disposition of: 3,131


    Item 5.
    Ownership of Five Percent or Less of a Class
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x .
     
     
     
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.
     
    Not Applicable
     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
     
    J.P. Morgan Securities LLC
    JPMorgan Chase Bank, National Association
    J.P. MORGAN SE
    J.P. Morgan (Suisse) SA
    J.P. Morgan Investment Management Inc.
    55I, LLC
    J.P. Morgan Private Wealth Advisors LLC
     
    Item 8.
    Identification and Classification of Members of the Group
     
    Not Applicable
     
    Item 9.
    Notice of Dissolution of Group
     
    Not Applicable
     
     
     

     
     
     
    Item 10.
    Certification
       
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.
     
     


    SIGNATURE


    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
     
      JPMORGAN CHASE & CO.

     
           
    Date: April 09, 2024
    By:
    /s/  Rachel Tsvaygoft  
        Name: Rachel Tsvaygoft  
        Title:  Vice President  
           
     
    Footnotes:


    Attention:
    Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)
     
     



    Get the next $EVH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EVH

    DatePrice TargetRatingAnalyst
    2/25/2026Overweight → Sector Weight
    KeyBanc Capital Markets
    11/13/2025$7.00Equal-Weight → Overweight
    Stephens
    11/13/2025$7.00Outperform
    BMO Capital Markets
    1/10/2025$15.00Buy
    Needham
    12/3/2024$36.00 → $29.00Buy
    BTIG Research
    11/8/2024$38.00 → $16.00Overweight → Equal-Weight
    Stephens
    10/11/2024$35.00Overweight
    KeyBanc Capital Markets
    8/9/2024$28.00 → $33.00Hold → Buy
    Truist
    More analyst ratings

    $EVH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Evolent announces appointment of Archie Mayani as chief product officer

    Industry veteran brings track record of innovation from GHX, Change Healthcare, UnitedHealth Group and Amazon.WASHINGTON, March 19, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced the appointment of health care technology leader and AI innovator Archie Mayani as chief product officer (CPO).Mayani brings more than two decades of leadership experience across health care, enterprise platforms, and AI, with a history of building products that improve clinical and business outcomes at scale.Before joining Evolent, she served as CPO at GHX, where she helped pioneer AI-powered capabilitie

    3/19/26 8:45:00 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Foodsmart Appoints Cityblock Health Co-Founder and CEO Dr. Toyin Ajayi to Board of Directors

    National leader in value-based care joins as Foodsmart scales foodcare for Medicaid populationsSAN FRANCISCO, March 18, 2026 /PRNewswire/ -- Foodsmart, the leading telenutrition and foodcare provider nationwide, today announced the appointment of Dr. Toyin Ajayi to its Board of Directors. A board-certified Family Medicine physician and the co-founder and CEO of Cityblock Health, Dr. Ajayi brings deep experience serving Medicaid and dually eligible populations through value-based care models designed to improve outcomes and lower total cost of care. For millions of Americans, foo

    3/18/26 9:11:00 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Evolent to Participate in Upcoming Investor Conferences

    WASHINGTON, Feb. 26, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced that members of its executive management team will participate in upcoming investor conferences. A live audio-only webcast and replay for these events will be available on the "Events and Presentations" section of Evolent's investor relations website. Presentation webcast times will be posted on the website as they become available.Cowen 46th Annual Healthcare Conference at the Boston Marriott Copley in Boston, Massachusetts on March 3, 2026.Oppenheimer 36th Annual Healthcare MedTech and Services Conference to be

    2/26/26 5:00:00 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evolent Health downgraded by KeyBanc Capital Markets

    KeyBanc Capital Markets downgraded Evolent Health from Overweight to Sector Weight

    2/25/26 7:39:36 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Evolent Health upgraded by Stephens with a new price target

    Stephens upgraded Evolent Health from Equal-Weight to Overweight and set a new price target of $7.00

    11/13/25 9:38:39 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    BMO Capital Markets initiated coverage on Evolent Health with a new price target

    BMO Capital Markets initiated coverage of Evolent Health with a rating of Outperform and set a new price target of $7.00

    11/13/25 9:13:18 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Springstubb Brendan B bought $38,199 worth of shares (10,000 units at $3.82), increasing direct ownership by 20% to 58,821 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    11/19/25 4:23:02 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Director Holder Diane bought $25,518 worth of shares (2,735 units at $9.33), increasing direct ownership by 4% to 70,584 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    3/10/25 8:20:54 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    PRESIDENT Mccarthy Daniel Joseph bought $99,470 worth of shares (11,040 units at $9.01), increasing direct ownership by 3% to 389,004 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    3/10/25 8:18:12 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Blackley Seth covered exercise/tax liability with 51,326 shares and was granted 58,921 shares, increasing direct ownership by 0.92% to 836,962 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    3/4/26 6:02:31 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    General Counsel Weinberg Jonathan was granted 4,910 shares and covered exercise/tax liability with 14,577 shares, decreasing direct ownership by 4% to 244,512 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    3/4/26 5:58:37 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    PRESIDENT Mccarthy Daniel Joseph covered exercise/tax liability with 50,030 shares and was granted 39,281 shares, decreasing direct ownership by 2% to 423,022 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    3/4/26 5:53:20 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    SEC Filings

    View All

    Evolent Health Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Evolent Health, Inc. (0001628908) (Filer)

    2/24/26 4:12:45 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SCHEDULE 13G/A filed by Evolent Health Inc

    SCHEDULE 13G/A - Evolent Health, Inc. (0001628908) (Subject)

    2/13/26 1:22:30 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SCHEDULE 13G/A filed by Evolent Health Inc

    SCHEDULE 13G/A - Evolent Health, Inc. (0001628908) (Subject)

    2/11/26 1:30:10 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    Leadership Updates

    Live Leadership Updates

    View All

    Evolent announces appointment of Archie Mayani as chief product officer

    Industry veteran brings track record of innovation from GHX, Change Healthcare, UnitedHealth Group and Amazon.WASHINGTON, March 19, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced the appointment of health care technology leader and AI innovator Archie Mayani as chief product officer (CPO).Mayani brings more than two decades of leadership experience across health care, enterprise platforms, and AI, with a history of building products that improve clinical and business outcomes at scale.Before joining Evolent, she served as CPO at GHX, where she helped pioneer AI-powered capabilitie

    3/19/26 8:45:00 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Foodsmart Appoints Cityblock Health Co-Founder and CEO Dr. Toyin Ajayi to Board of Directors

    National leader in value-based care joins as Foodsmart scales foodcare for Medicaid populationsSAN FRANCISCO, March 18, 2026 /PRNewswire/ -- Foodsmart, the leading telenutrition and foodcare provider nationwide, today announced the appointment of Dr. Toyin Ajayi to its Board of Directors. A board-certified Family Medicine physician and the co-founder and CEO of Cityblock Health, Dr. Ajayi brings deep experience serving Medicaid and dually eligible populations through value-based care models designed to improve outcomes and lower total cost of care. For millions of Americans, foo

    3/18/26 9:11:00 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Privia Health Expands Value-Based Care Footprint with Acquisition of Accountable Care Organization Business from Evolent Health

    ARLINGTON, Va., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (NASDAQ:PRVA) announced that it signed a definitive agreement to acquire an Accountable Care Organization (ACO) business from Evolent Health, Inc. (NYSE:EVH). The ACO business cares for over 120,000 attributed lives through the Medicare Shared Savings Program (MSSP), as well as various commercial and Medicare Advantage programs. With this transaction, Privia Health will now serve approximately 1.5 million attributed lives in value-based care (VBC) arrangements across commercial, Medicare, Medicare Advantage and Medicaid. Privia Health will pay $100 million in cash at closing and up to an additional $13 million su

    9/23/25 4:10:00 PM ET
    $EVH
    $PRVA
    Other Consumer Services
    Consumer Discretionary
    Medical/Nursing Services
    Health Care

    $EVH
    Financials

    Live finance-specific insights

    View All

    Evolent Announces Fourth Quarter 2025 Results and Full Year 2025 Results

    WASHINGTON, Feb. 24, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended December 31, 2025.Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "In 2025 we executed on our earnings targets, continued to grow market share, renewed customers at strong rates, and continued the migration of Performance Suite clients to our enhanced Performance Suite contract model. We believe our total forecasted revenue growth of approximat

    2/24/26 4:10:00 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Evolent To Release 2025 Fourth Quarter and Year-End Financial Results on Tuesday, February 24, 2026

    WASHINGTON, Feb. 4, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its 2025 fourth quarter and year-end financial results on Tuesday, February 24, 2026, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com. Analysts interested in asking questions during the live call should dial 855.940.9467, or 412.317.6034 for international callers, and reference the "Evolent call" 15 minutes prior to th

    2/4/26 11:02:00 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Evolent Announces Third Quarter 2025 Results

    Q3 2025 financial results ahead of expectations.Announces more than $500 million in newly-contracted annualized revenue to launch in 2026.Expands leadership team to support accelerating growth.WASHINGTON, Nov. 6, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended September 30, 2025. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "We are happy to deliver a strong quarter, in the top half of our guidance for both Ad

    11/6/25 4:10:00 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Evolent Health Inc

    SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)

    11/12/24 9:55:15 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Evolent Health Inc

    SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)

    8/7/24 7:47:40 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Evolent Health Inc

    SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)

    7/10/24 10:10:34 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary